Bibliography
- Benjamin SM, Valdez R, Geiss LS, et al. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 2003;26(3):645-9
- Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290(14):1884-90
- Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403
- Franz M, editor. Diabetes and complications. 4th edition. Chicago; 2001
- ASSOCIATION AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007;30(Suppl 1):S42-7
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86
- Haycox A. Insulin aspart: an evidence-based medicine review. Clin Drug Investig 2004;24(12):695-717
- Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25(5):883-8
- Foseca VA, editor. Clinical diabetes: translating research into practice. 1st edition. Philadelphia: Saunders; 2006
- Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19(5):393-9
- Dewitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289(17):2254-64
- Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56(5):399-403
- Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997;20(10):1612-4
- Chen JW, Lauritzen T, Christiansen JJ, et al. Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: a randomized double-blinded crossover study. Diabet Med 2005;22(3):273-7
- Clausen WH, De Gaetano A, Volund A. Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling. Diabetologia 2006;49(9):2030-8
- Mortensen HB, Aanstoot HJ, Annan K, et al. Biphasic insulin aspart 30 – treatment options in children and adolescents. Eur Endocr Dis 2006;23-6
- Clements MR, Tits J, Kinsley BT, et al. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. Diabetes Obes Metab 2008;10(3):229-37
- Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006;66(1):31-49
- Stenstrom G, Gottsater A, Bakhtadze E, et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 2005;54(Suppl 2):S68-72
- Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin N Am 2001;30(4):935-82
- Rosenstock J. Basal insulin supplementation in type 2 diabetes; refining the tactics. Am J Med 2004;116(Suppl 3A):10S-16S